based Capsida Biotherapeutics (Capsida) has announced its slate of seven scientific presentations, three oral and four in poster form, that have been ... communities who so desperately need them.” ...

today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR ...

CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts ...

IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible ...

Abstract and poster presentation details are below: Title: "Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with ...

Abstract Title: SynKIR-CAR T Cell Advanced Research (STAR)-101 phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma. The KIR ...

Additionally, two abstracts on another drug, AFM24, in combination with atezolizumab for treating non-small cell lung cancer (NSCLC) have been accepted for poster presentations. The oral ...

The max poster file size is 6MB. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. All submitted posters will be reviewed, and ...

TAIPEI, Taiwan, April 23, 2025 (GLOBE NEWSWIRE) — OBI Pharma, Inc. (TPEx: 4174. TWO) today announced nonclinical data for OBI-902, a potential best-in-class anti-TROP2 ADC developed using the ...

Late-Breaking Abstracts (LBAs), including Plenary abstracts, will be released at 7:00 AM (CT)/8:00 AM (ET) on the day of presentation ... the abstract is published by ASCO? For example, are we allowed ...

For more and to view the abstract, visit the AACR Annual Meeting ... negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not ...

Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE ...